UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Insulin resistance and bone: a biological partnership

Acta diabetologica, 2018-04, Vol.55 (4), p.305-314

2018

Volltextzugriff (PDF)

Bisphosphonates inactivate human EGFRs to exert antitumor actions

Proceedings of the National Academy of Sciences - PNAS, 2014-12, Vol.111 (50), p.17989-17994

2014

Volltextzugriff (PDF)

Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2014-12, Vol.111 (50), p.17995-18000

2014

Volltextzugriff (PDF)

Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update

Journal of clinical pharmacology, 2004-09, Vol.44 (9), p.951-965

2004

Volltextzugriff (PDF)

Calcineurin Regulates Bone Formation by the Osteoblast

Proceedings of the National Academy of Sciences - PNAS, 2005-11, Vol.102 (47), p.17130-17135

2005

Volltextzugriff (PDF)

Update of current therapeutic options for the treatment of postmenopausal osteoporosis

Clinical therapeutics, 2006-02, Vol.28 (2), p.151-173

Epstein, Solomon

2006

Volltextzugriff (PDF)

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema

Diabetes care, 2016-02, Vol.39 (2), p.179-186

2016

Volltextzugriff (PDF)

Bone loss or lost bone: Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss

Current osteoporosis reports, 2009-12, Vol.7 (4), p.118-126

2009

Volltextzugriff (PDF)

Long-term proton pump inhibitor therapy and risk of hip fracture

JAMA : the journal of the American Medical Association, 2006-12, Vol.296 (24), p.2947

2006

Volltextzugriff (PDF)

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Clinical therapeutics, 2009-04, Vol.31 (4), p.751-761

2009

Volltextzugriff (PDF)

Evaluating the antifracture efficacy of bisphosphonates

Reviews on recent clinical trials, 2009-05, Vol.4 (2), p.122-130

2009

Volltextzugriff (PDF)

Nonsteroid Immune Modulators and Bone Disease

Annals of the New York Academy of Sciences, 2006-04, Vol.1068 (1), p.284-296

2006

Volltextzugriff (PDF)

The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy

Mayo Clinic proceedings, 2005-03, Vol.80 (3), p.379-388

Epstein, Solomon

2005

Volltextzugriff (PDF)

A novel mechanism for coupling cellular intermediary metabolism to cytosolic Ca2+ signaling via CD38/ADP‐ribosyl cyclase, a putative intracellular NAD+ sensor

The FASEB journal, 2002-03, Vol.16 (3), p.302-314

2002

Volltextzugriff (PDF)

A Unified Pathophysiological Construct of Diabetes and its Complications

Trends in endocrinology and metabolism, 2017-09, Vol.28 (9), p.645-655

2017

Volltextzugriff (PDF)

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the [Beta]-Cell-Centric Classification Schema

Diabetes care, 2016-02, Vol.39 (2), p.179

2016

Volltextzugriff (PDF)

Rapamycin: A bone sparing immunosuppressant?

Journal of bone and mineral research, 1995-05, Vol.10 (5), p.760-768

1995

Volltextzugriff (PDF)

Response to Comment on Schwartz et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. Diabetes Care 2016;39:179-186

Diabetes care, 2016-08, Vol.39 (8), p.e129-e130

2016

Volltextzugriff (PDF)

Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens

Current osteoporosis reports, 2006-03, Vol.4 (1), p.14-20

Epstein, Solomon

2006

Volltextzugriff (PDF)

Osteoporosis and diabetes mellitus

Reviews in endocrine & metabolic disorders, 2004-08, Vol.5 (3), p.261-268

2004

Volltextzugriff (PDF)

Disorders Associated With Acute Rapid and Severe Bone Loss

Journal of bone and mineral research, 2003-12, Vol.18 (12), p.2083-2094

2003

Volltextzugriff (PDF)

Modeling of Serum C-Telopeptide Levels with Daily and Monthly Oral Ibandronate in Humans

Annals of the New York Academy of Sciences, 2006-04, Vol.1068 (1), p.560-563

2006

Volltextzugriff (PDF)

Blocking FSH Induces Thermogenic Adipose Tissue and Reduces Body Fat

Obstetrical & gynecological survey, 2017-10, Vol.72 (10), p.601-602

2017

Volltextzugriff (PDF)

Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts

American journal of physiology. Renal physiology, 2007-01, Vol.292 (1), p.F285-F291

2007

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Englisch
(148)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Life Sciences & Biomedicine
(79)
Humans
(58)
Biological And Medical Sciences
(43)
Male
(40)
Animals
(38)
Female
(38)
Medical Sciences
(29)
Fundamental And Applied Biological Sciences. Psychology
(15)
Osteoporosis
(14)
Middle Aged
(13)
General & Internal Medicine
(11)
Medicine, General & Internal
(11)
Aged
(10)
Child
(10)
Child, Preschool
(10)
Endocrinology & Metabolism
(10)
Infant
(10)
Pharmacology. Drug Treatments
(10)
Physiology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Insulin resistance and bone: a biological partnership

Bisphosphonates inactivate human EGFRs to exert antitumor actions

Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer

Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update

Calcineurin Regulates Bone Formation by the Osteoblast

Update of current therapeutic options for the treatment of postmenopausal osteoporosis

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema

Bone loss or lost bone: Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss

Long-term proton pump inhibitor therapy and risk of hip fracture

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Evaluating the antifracture efficacy of bisphosphonates

Blocking FSH induces thermogenic adipose tissue and reduces body fat

Nonsteroid Immune Modulators and Bone Disease

The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy

A novel mechanism for coupling cellular intermediary metabolism to cytosolic Ca2+ signaling via CD38/ADP‐ribosyl cyclase, a putative intracellular NAD+ sensor

A Unified Pathophysiological Construct of Diabetes and its Complications

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the [Beta]-Cell-Centric Classification Schema

Rapamycin: A bone sparing immunosuppressant?

Response to Comment on Schwartz et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. Diabetes Care 2016;39:179-186

Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens

Osteoporosis and diabetes mellitus

Disorders Associated With Acute Rapid and Severe Bone Loss

Modeling of Serum C-Telopeptide Levels with Daily and Monthly Oral Ibandronate in Humans

Blocking FSH Induces Thermogenic Adipose Tissue and Reduces Body Fat

Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts

Suchergebnisse filtern